European Medicine Agency's Pott welcomes criticism of EPARs
This article was originally published in SRA
Executive Summary
The European Medicines Agency has said it welcomes criticism of its European public assessment reports following a recent call for an improvement in the way that the agency uses the makes public details about clinical trial results through the reports1,2.